Core Points - Suzhou Fengbei Biotechnology Co., Ltd. has received approval for its initial public offering (IPO) of RMB ordinary shares (A-shares) and listing on the main board from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The total number of shares for this issuance is set at 35.9 million, with an initial strategic placement of 7.18 million shares, accounting for 20% of the total issuance [2] - The final strategic placement quantity is 4.083297 million shares, which is 11.37% of the total issuance, with the difference being allocated to offline issuance [2] Issuance Structure - The issuance will combine strategic placement, offline pricing for qualified investors, and online pricing for public investors holding non-restricted A-shares and depository receipts [1] - After the strategic placement adjustment, the offline issuance will consist of 20.328703 million shares (63.89% of the remaining shares), while the online issuance will consist of 11.488 million shares (36.11% of the remaining shares) [2][7] Pricing and Payment - The issuance price is set at RMB 24.49 per share, with the online offering of 11.488 million shares scheduled for October 27, 2025 [2] - Investors must fulfill their payment obligations by October 29, 2025, with specific instructions for offline and online investors regarding payment procedures [3][4] Subscription and Allocation - The initial online subscription saw 13,647,883 valid applications, totaling 101,265,777,500 shares, resulting in an initial online winning rate of 0.01134441% [6] - Following the implementation of the allocation mechanism, the final online winning rate increased to 0.02391232% after reallocating shares from offline to online due to high demand [8] Draw and Announcement - The online draw for the issuance is scheduled for October 28, 2025, with results to be announced on October 29, 2025 [9]
苏州丰倍生物科技股份有限公司首次公开发行股票并在主板上市网上发行申购情况及中签率公告
Shang Hai Zheng Quan Bao·2025-10-27 21:42